Advancing the Pharmaceutical Potential of Bioinorganic Hybrid Lipid‐Based Assemblies

Abstract

Bioinspired lipid assemblies that mimic the elaborate architecture of natural membranes have fascinated researchers for a long time. These lipid assemblies have gone from being just an imperative platform for biophysical research to a pharmaceutical delivery system for biomedical applications. Despite success, these organized nanosystems are often subject to the mechanical instability and limited theranostic capability without adding any inconvenient modifications. To reach their advanced pharmaceutical potential, various bioinorganic hybrid lipid‐based assembles, which provide new opportunities to synergistically complement and improve therapeutic/diagnostic potential of existing lipid‐based nanomedicine with distinct mechanisms containing inorganic embedded surfactants, have recently been developed.

Polyfunctional Nanosystems on Amphiphilic and Hybrid Platform: Self-Assembly, Mesogenic Properties and Application

“…Ван Дж. и соавторы [71] провели сопоставление липосомальных формулировок с керасомальными. Первым была присуща большая скорость высвобождения лекарства и биосовместимость, в то время как вторые характеризовались большей механической стабильностью.…”

An in Silico Approach to Reveal the Nanodisc Formulation of Doxorubicin

“…Endogenous and synthetic lipoproteins, such as high-density lipoprotein (HDL)-like nanodiscs, have rapidly evolved as a promising DDS for small molecules, peptides, and nucleic acids because of their intrinsic long in vivo half-lives and passive targeting properties (Kuai et al, 2017;Kuai et al, 2018;Kadiyala et al, 2019). Therefore, nanodisc drug formulation has attracted significant attention in the field of nanomedicine (Lacko et al, 2015;Wang et al, 2018;Tang et al, 2021). Several studies regarding nanodisc-based DOX delivery that employed different encapsulation strategies have shown increased efficacy and reduced side effects in anticancer therapy (Murakami et al, 2010;Yuan et al, 2013;Wang et al, 2014;Kuai et al, 2018).…”

De novo Design of G Protein-Coupled Receptor 40 Peptide Agonists for Type 2 Diabetes Mellitus Based on Artificial Intelligence and Site-Directed Mutagenesis

“…Besides, the blood circulation time is important for the duration of action. In this context, peptide drugs can provide tunable circulation times through extended sequence engineering or drug delivery systems (Zorzi et al, 2017;Wang et al, 2018Wang et al, , 2020. In the case of membrane protein, the binding site of GPR40 was located in the extracellular part, so peptides targeting GPR40 can act without membrane penetration.…”